Rajesh Agarwal Selected Research

isosilybin A

10/2010	Isosilybin A induces apoptosis in human prostate cancer cells via targeting Akt, NF-κB, and androgen receptor signaling.
4/2010	Large-scale isolation of flavonolignans from Silybum marianum extract affords new minor constituents and preliminary structure-activity relationships.
7/2007	Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells.
5/2005	Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rajesh Agarwal Research Topics

Disease

156	Neoplasms (Cancer) 01/2022 - 03/2002
82	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 03/2002
47	Carcinoma (Carcinomatosis) 01/2018 - 03/2002
37	Carcinogenesis 01/2022 - 08/2002
22	Colorectal Neoplasms (Colorectal Cancer) 02/2021 - 10/2006
20	Body Weight (Weight, Body) 01/2017 - 01/2004
19	Inflammation (Inflammations) 12/2017 - 09/2005
16	Skin Neoplasms (Skin Cancer) 05/2020 - 03/2002
14	Adenocarcinoma 01/2022 - 11/2003
14	Hypoxia (Hypoxemia) 02/2020 - 09/2006
14	Neoplasm Metastasis (Metastasis) 01/2018 - 06/2003
14	Lung Neoplasms (Lung Cancer) 01/2017 - 06/2006
14	Wounds and Injuries (Trauma) 02/2016 - 04/2011
8	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 06/2013
8	Colonic Neoplasms (Colon Cancer) 01/2018 - 11/2003
8	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017 - 05/2003
7	Corneal Injuries 01/2022 - 01/2016
6	Squamous Cell Carcinoma of Head and Neck 11/2017 - 08/2011
6	Urinary Bladder Neoplasms (Bladder Cancer) 11/2013 - 12/2003
5	Ataxia Telangiectasia (Louis Bar Syndrome) 04/2012 - 11/2005
5	Retinoblastoma (Glioblastoma, Retinal) 08/2009 - 03/2002
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 03/2002
4	Basal Cell Carcinoma (Rodent Ulcer) 01/2022 - 01/2016
4	Edema (Dropsy) 12/2016 - 03/2008
4	Breast Neoplasms (Breast Cancer) 05/2016 - 02/2004
4	Papilloma (Papillomatosis) 01/2008 - 03/2002
3	Adenocarcinoma of Lung 01/2018 - 01/2009
3	Necrosis 01/2017 - 06/2010

Drug/Important Bio-Agent (IBA)

100	Silybin (Lagosa)IBA 01/2022 - 03/2002
33	Grape Seed ExtractIBA 01/2019 - 11/2002
25	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 09/2003
22	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2002
21	Biological ProductsIBA 01/2022 - 03/2002
19	Biomarkers (Surrogate Marker)IBA 01/2021 - 09/2003
17	SilymarinIBA 05/2020 - 03/2002
15	PhytochemicalsIBA 01/2015 - 05/2002
14	Mustard Gas (Sulfur Mustard)IBA 01/2022 - 06/2010
14	AndrogensIBA 01/2018 - 05/2002
12	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2016 - 03/2002
11	FlavonoidsIBA 01/2016 - 03/2002
11	Phytic Acid (Inositol Hexaphosphate)IBA 01/2013 - 03/2003
10	Pharmaceutical PreparationsIBA 12/2020 - 11/2002
10	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 10/2019 - 06/2006
10	Phosphotransferases (Kinase)IBA 01/2018 - 09/2004
10	Transcription Factors (Transcription Factor)IBA 05/2016 - 09/2004
10	NF-kappa B (NF-kB)IBA 03/2013 - 09/2003
10	CaspasesIBA 04/2012 - 11/2002
9	Mechlorethamine (Nitrogen Mustard)FDA Link 01/2022 - 10/2012
9	Irritants (Vesicants)IBA 01/2022 - 01/2012
9	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 10/2012 - 06/2006
8	2-chloroethyl ethyl sulfideIBA 07/2014 - 03/2009
7	AzoxymethaneIBA 02/2021 - 10/2008
7	CyclinsIBA 01/2017 - 03/2003
7	AntioxidantsIBA 12/2015 - 06/2002
7	Cyclin-Dependent Kinases (cdk Proteins)IBA 05/2013 - 11/2003
7	CarcinogensIBA 01/2013 - 08/2002
6	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2018 - 08/2002
6	Cyclin D1IBA 01/2016 - 06/2006
6	EnzymesIBA 09/2015 - 06/2006
6	CytokinesIBA 06/2014 - 07/2008
6	flavanoneIBA 10/2012 - 12/2003
6	milk-thistle extractIBA 01/2012 - 06/2002
5	Glucose (Dextrose)FDA LinkGeneric 09/2019 - 05/2009
5	procyanidin B2IBA 01/2019 - 04/2010
5	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2017 - 11/2002
5	Antineoplastic Agents (Antineoplastics)IBA 01/2016 - 02/2005
5	DNA (Deoxyribonucleic Acid)IBA 01/2015 - 09/2003
5	Cytotoxins (Cytolysins)IBA 01/2013 - 02/2004
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2012 - 08/2002
5	Caspase 3 (Caspase-3)IBA 08/2011 - 09/2004
5	beta CateninIBA 07/2010 - 12/2009
5	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA 05/2005 - 03/2002
4	LipidsIBA 12/2020 - 08/2015
4	Matrix Metalloproteinases (MMPs)IBA 01/2020 - 09/2006
4	Matrix Metalloproteinase 9 (Gelatinase B)IBA 10/2019 - 09/2011
4	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 02/2016 - 05/2006
4	ResveratrolIBA 04/2015 - 11/2005
4	Cadherins (E-Cadherin)IBA 02/2014 - 12/2008
4	FlavonolignansIBA 02/2013 - 05/2005
4	Androgen Receptors (Androgen Receptor)IBA 08/2012 - 03/2003
4	isosilybin AIBA 10/2010 - 05/2005
4	Drinking WaterIBA 12/2009 - 12/2007
4	Gallic AcidIBA 09/2009 - 07/2006
4	SurvivinIBA 01/2008 - 12/2003
4	Insulin-Like Growth Factor Binding Protein 3IBA 12/2007 - 09/2003
3	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 10/2012
3	Gemcitabine FDA Link 10/2020 - 04/2015
3	nintedanibIBA 02/2020 - 05/2017
3	Interleukin-8 (Interleukin 8)IBA 10/2019 - 08/2014
3	MicroRNAs (MicroRNA)IBA 03/2018 - 07/2013
3	Indicators and Reagents (Reagents)IBA 01/2018 - 09/2015
3	CateninsIBA 01/2018 - 09/2010
3	acacetinIBA 01/2017 - 04/2005
3	fisetinIBA 01/2017 - 02/2012
3	Mitogen-Activated Protein KinasesIBA 02/2016 - 03/2002

Therapy/Procedure

43	Therapeutics 12/2020 - 08/2002
29	Chemoprevention 01/2018 - 01/2004
11	Drug Therapy (Chemotherapy) 01/2018 - 09/2003
3	Oral Administration 12/2020 - 07/2013
3	Radiotherapy 01/2018 - 10/2008